{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T01:24:39Z","timestamp":1759541079826},"reference-count":91,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1097\/crd.0000000000000062","type":"journal-article","created":{"date-parts":[[2015,3,5]],"date-time":"2015-03-05T11:38:04Z","timestamp":1425555484000},"page":"252-260","source":"Crossref","is-referenced-by-count":6,"title":["Therapeutic Role of Innovative Anti-Inflammatory Medications in the Prevention of Acute Coronary Syndrome"],"prefix":"10.1097","volume":"23","author":[{"given":"Raymond Anthony","family":"Pashun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-6-20210203","first-page":"1","article-title":"Deaths: final data for 2009.","volume":"60","author":"Kochanek","year":"2011","journal-title":"CDC: Natil Vital Stat Reports"},{"key":"R2-6-20210203","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1161\/01.CIR.90.4.2126","article-title":"Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology.","volume":"90","author":"Fuster","year":"1994","journal-title":"Circulation"},{"key":"R3-6-20210203","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jacc.2013.10.041","article-title":"The year in acute coronary syndrome.","volume":"63","author":"Giugliano","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R4-6-20210203","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMra1216063","article-title":"Mechanisms of acute coronary syndromes and their implications for therapy.","volume":"368","author":"Libby","year":"2013","journal-title":"N Engl J Med"},{"key":"R6-6-20210203","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1161\/01.CIR.91.11.2844","article-title":"Molecular bases of the acute coronary syndromes.","volume":"91","author":"Libby","year":"1995","journal-title":"Circulation"},{"key":"R7-6-20210203","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/0735-1097(88)90356-7","article-title":"Angiographic progression of coronary artery disease and the development of myocardial infarction.","volume":"12","author":"Ambrose","year":"1988","journal-title":"J Am Coll Cardiol"},{"key":"R8-6-20210203","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0735-1097(86)80455-7","article-title":"Angiographic evolution of coronary artery morphology in unstable angina.","volume":"7","author":"Ambrose","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"R9-6-20210203","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa066139","article-title":"Occluded Artery Trial Investigators. Coronary intervention for persistent occlusion after myocardial infarction.","volume":"355","author":"Hochman","year":"2006","journal-title":"N Engl J Med"},{"key":"R10-6-20210203","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa070829","article-title":"COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease.","volume":"356","author":"Boden","year":"2007","journal-title":"N Engl J Med"},{"key":"R11-6-20210203","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/eurheartj\/ehs411","article-title":"Update on acute coronary syndromes: the pathologists view.","volume":"34","author":"Falk","year":"2013","journal-title":"Eur Heart J"},{"key":"R12-6-20210203","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00001573-200109000-00006","article-title":"The thin-cap fibroatheroma: a type of vulnerable plaque: the major precursor lesion to acute coronary syndromes.","volume":"16","author":"Kolodgie","year":"2001","journal-title":"Curr Opin Cardiol"},{"key":"R13-6-20210203","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1161\/CIRCULATIONAHA.111.047431","article-title":"Acute coronary events.","volume":"125","author":"Arbab-Zadeh","year":"2012","journal-title":"Circulation"},{"key":"R14-6-20210203","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1161\/01.CIR.104.3.365","article-title":"Current concepts of the pathogenesis of the acute coronary syndromes.","volume":"104","author":"Libby","year":"2001","journal-title":"Circulation"},{"key":"R15-6-20210203","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1161\/01.ATV.11.5.1223","article-title":"Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells.","volume":"11","author":"Amento","year":"1991","journal-title":"Arterioscler Thromb"},{"key":"R16-6-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2012.07.064","article-title":"Pathogenesis of acute coronary syndromes.","volume":"61","author":"Crea","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R17-6-20210203","first-page":"169","article-title":"Detection of activated T lymphocytes in the human atherosclerotic plaque.","volume":"135","author":"Hansson","year":"1989","journal-title":"Am J Pathol"},{"key":"R18-6-20210203","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1161\/01.CIR.89.1.36","article-title":"Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology.","volume":"89","author":"van der Wal","year":"1994","journal-title":"Circulation"},{"key":"R19-6-20210203","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/01.crd.0000105000.46909.81","article-title":"Elastinolytic matrix metalloproteinases and their inhibitors as therapeutic targets in atherosclerotic plaque instability.","volume":"12","author":"Smeglin","year":"2004","journal-title":"Cardiol Rev"},{"key":"R20-6-20210203","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1161\/01.RES.75.1.181","article-title":"Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion.","volume":"75","author":"Galis","year":"1994","journal-title":"Circ Res"},{"key":"R21-6-20210203","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1172\/JCI117619","article-title":"Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques.","volume":"94","author":"Galis","year":"1994","journal-title":"J Clin Invest"},{"key":"R22-6-20210203","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1161\/01.CIR.92.6.1393","article-title":"Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis.","volume":"92","author":"Nikkari","year":"1995","journal-title":"Circulation"},{"key":"R23-6-20210203","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1161\/hc4101.097419","article-title":"Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling.","volume":"104","author":"Herman","year":"2001","journal-title":"Circulation"},{"key":"R24-6-20210203","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1161\/01.CIR.99.19.2503","article-title":"Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques.","volume":"99","author":"Sukhova","year":"1999","journal-title":"Circulation"},{"key":"R25-6-20210203","first-page":"1565","article-title":"Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture.","volume":"92","author":"Shah","year":"1995","journal-title":"Circulation"},{"key":"R26-6-20210203","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1161\/01.CIR.96.2.396","article-title":"Activation of monocytemacrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor.","volume":"96","author":"Mach","year":"1997","journal-title":"Circulation"},{"key":"R27-6-20210203","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/CRD.0000000000000021","article-title":"Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy.","volume":"22","author":"Hartman","year":"2014","journal-title":"Cardiol Rev"},{"key":"R29-6-20210203","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1161\/01.ATV.13.2.254","article-title":"Plaque changes and arterial enlargement in atherosclerotic monkeys after manipulation of diet and social environment.","volume":"13","author":"Kaplan","year":"1993","journal-title":"Arterioscler Thromb"},{"key":"R30-6-20210203","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1161\/01.ATV.15.11.1938","article-title":"Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits.","volume":"15","author":"Shiomi","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R31-6-20210203","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1161\/01.CIR.97.24.2433","article-title":"Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization.","volume":"97","author":"Aikawa","year":"1998","journal-title":"Circulation"},{"key":"R32-6-20210203","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/S0735-1097(98)00487-2","article-title":"HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis.","volume":"32","author":"Bustos","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"R33-6-20210203","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1093\/eurheartj\/ehu203","article-title":"Anti-inflammatory therapies for cardiovascular disease.","volume":"35","author":"Ridker","year":"2014","journal-title":"Eur Heart J"},{"key":"R34-6-20210203","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.2165\/11205470-000000000-00000","article-title":"Oral colchicine (Colcrys): in the treatment and prophylaxis of gout.","volume":"70","author":"Yang","year":"2010","journal-title":"Drugs"},{"key":"R35-6-20210203","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1056\/NEJMoa1208536","article-title":"ICAP Investigators. A randomized trial of colchicine for acute pericarditis.","volume":"369","author":"Imazio","year":"2013","journal-title":"N Engl J Med"},{"key":"R36-6-20210203","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s11926-008-0036-3","article-title":"Colchicine: its mechanism of action and efficacy in crystal-induced inflammation.","volume":"10","author":"Nuki","year":"2008","journal-title":"Curr Rheumatol Rep"},{"key":"R37-6-20210203","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/j.bmc.2007.11.076","article-title":"Docking and hydropathic scoring of polysubstituted pyrrole compounds with antitubulin activity.","volume":"16","author":"Tripathi","year":"2008","journal-title":"Bioorg Med Chem"},{"key":"R38-6-20210203","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/art.1780080438","article-title":"Colchicine inhibition of chemotaxis.","volume":"8","author":"Caner","year":"1965","journal-title":"Arthritis Rheum"},{"key":"R39-6-20210203","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/01.CIR.0000042674.89762.20","article-title":"Neutrophil infiltration of culprit lesions in acute coronary syndromes.","volume":"106","author":"Naruko","year":"2002","journal-title":"Circulation"},{"key":"R40-6-20210203","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.amjcard.2006.10.039","article-title":"Effect of colchicine (0.5mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease.","volume":"99","author":"Nidorf","year":"2007","journal-title":"Am J Cardiol"},{"key":"R41-6-20210203","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s11239-011-0637-y","article-title":"Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial.","volume":"33","author":"Raju","year":"2012","journal-title":"J Thromb Thrombolysis"},{"key":"R42-6-20210203","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.jacc.2013.08.726","article-title":"Colchicine and the heart: pushing the envelope.","volume":"62","author":"Deftereos","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R43-6-20210203","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3899\/jrheum.111533","article-title":"Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout.","volume":"39","author":"Crittenden","year":"2012","journal-title":"J Rheumatol"},{"key":"R44-6-20210203","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease.","volume":"61","author":"Nidorf","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R45-6-20210203","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jchf.2013.11.006","article-title":"Anti-inflammatory treatment with colchicine in stable chronic heart failure: a prospective, randomized study.","volume":"2","author":"Deftereos","year":"2014","journal-title":"JACC Heart Fail"},{"issue":"Pt 2","key":"R46-6-20210203","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1042\/bj3380479","article-title":"Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor.","volume":"338","author":"MacPhee","year":"1999","journal-title":"Biochem J"},{"key":"R47-6-20210203","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1161\/CIRCULATIONAHA.105.612630","article-title":"Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial.","volume":"113","author":"ODonoghue","year":"2006","journal-title":"Circulation"},{"key":"R48-6-20210203","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1161\/01.CIR.0000154553.12214.CD","article-title":"Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study.","volume":"111","author":"Oei","year":"2005","journal-title":"Circulation"},{"key":"R49-6-20210203","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1161\/01.ATV.0000222983.73369.c8","article-title":"Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress.","volume":"26","author":"Koenig","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R50-6-20210203","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1161\/01.ATV.0000160551.21962.a7","article-title":"Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target.","volume":"25","author":"Zalewski","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R51-6-20210203","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1161\/01.ATV.0000244681.72738.bc","article-title":"Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis.","volume":"26","author":"Kolodgie","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R52-6-20210203","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.clinthera.2013.07.332","article-title":"Targeting the unstable plaque in acute coronary syndromes.","volume":"35","author":"Thompson","year":"2013","journal-title":"Clin Ther"},{"key":"R53-6-20210203","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.atherosclerosis.2006.05.001","article-title":"Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses.","volume":"191","author":"Shi","year":"2007","journal-title":"Atherosclerosis"},{"key":"R54-6-20210203","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/CRD.0b013e3181b2434e","article-title":"Lipoprotein-associated phospholipase A2: an independent predictor of cardiovascular risk and a novel target for immunomodulation therapy.","volume":"17","author":"Khakpour","year":"2009","journal-title":"Cardiol Rev"},{"key":"R56-6-20210203","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1161\/CIRCULATIONAHA.108.771899","article-title":"Integrated Biomarker and Imaging Study-2 Investigators. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque.","volume":"118","author":"Serruys","year":"2008","journal-title":"Circulation"},{"key":"R58-6-20210203","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s10554-011-9882-6","article-title":"Relationship between cardiovascular risk factors and biomarkers with necrotic core and atheroma size: a serial intravascular ultrasound radiofrequency data analysis.","volume":"28","author":"Garcia-Garcia","year":"2012","journal-title":"Int J Cardiovasc Imaging"},{"key":"R59-6-20210203","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ahj.2010.07.006","article-title":"Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease.","volume":"160","author":"White","year":"2010","journal-title":"Am Heart J"},{"key":"R61-6-20210203","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/jama.2014.11061","article-title":"SOLID-TIMI 52 Investigators. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.","volume":"312","author":"ODonoghue","year":"2014","journal-title":"JAMA"},{"key":"R62-6-20210203","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1093\/eurheartj\/ehs148","article-title":"Phospholipase A2 enzymes and the risk of atherosclerosis.","volume":"33","author":"Rosenson","year":"2012","journal-title":"Eur Heart J"},{"key":"R63-6-20210203","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1161\/ATVBAHA.112.300309","article-title":"Group X secreted phospholipase A2 limits the development of atherosclerosis in LDL receptor-null mice.","volume":"33","author":"Ait-Oufella","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R64-6-20210203","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10557-008-6135-6","article-title":"Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiological evidence.","volume":"23","author":"Koenig","year":"2009","journal-title":"Cardiovasc Drugs Ther"},{"key":"R65-6-20210203","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/01.ATV.19.5.1284","article-title":"Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2.","volume":"19","author":"Ivandic","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R66-6-20210203","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0021-9150(95)05604-1","article-title":"Secretory group II phospholipase A2 in human atherosclerotic plaques.","volume":"118","author":"Menschikowski","year":"1995","journal-title":"Atherosclerosis"},{"key":"R67-6-20210203","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s10557-011-6358-9","article-title":"Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial.","volume":"26","author":"Nicholls","year":"2012","journal-title":"Cardiovasc Drugs Ther"},{"key":"R68-6-20210203","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1001\/jama.2013.282836","article-title":"VISTA-16 Investigators. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.","volume":"311","author":"Nicholls","year":"2014","journal-title":"JAMA"},{"key":"R69-6-20210203","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/CIRCULATIONAHA.111.071886","article-title":"New therapeutic targets in cardiology: p38 alpha mitogen-activated protein kinase for ischemic heart disease.","volume":"126","author":"Denise Martin","year":"2012","journal-title":"Circulation"},{"key":"R70-6-20210203","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.yjmcc.2010.10.021","article-title":"The p38 mitogen-activated protein kinase pathway-a potential target for intervention in infarction, hypertrophy, and heart failure.","volume":"51","author":"Marber","year":"2011","journal-title":"J Mol Cell Cardiol"},{"key":"R71-6-20210203","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.ddmec.2010.07.006","article-title":"Developing small molecules to inhibit kinases unkind to the heart: p38 MAPK as a case in point.","volume":"7","author":"Marber","year":"2010","journal-title":"Drug Discov Today Dis Mech"},{"key":"R72-6-20210203","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1161\/01.CIR.99.13.1685","article-title":"Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion.","volume":"99","author":"Ma","year":"1999","journal-title":"Circulation"},{"key":"R73-6-20210203","doi-asserted-by":"crossref","first-page":"H1972","DOI":"10.1152\/ajpheart.00043.2006","article-title":"Selective inhibition of p38alpha MAPK improves cardiac function and reduces myocardial apoptosis in rat model of myocardial injury.","volume":"291","author":"Li","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R74-6-20210203","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/FJC.0b013e318279b7b1","article-title":"Inhibition of p38 MAPK during ischemia, but not reperfusion, effectively attenuates fatal arrhythmia in ischemiareperfusion heart.","volume":"61","author":"Surinkaew","year":"2013","journal-title":"J Cardiovasc Pharmacol"},{"key":"R75-6-20210203","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(14)60417-7","article-title":"SOLSTICE Investigators. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial.","volume":"384","author":"Newby","year":"2014","journal-title":"Lancet"},{"key":"R76-6-20210203","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/CRD.0000000000000022","article-title":"Interleukin 1: a proinflammatory target for preventing atherosclerotic heart disease.","volume":"22","author":"McCarty","year":"2014","journal-title":"Cardiol Rev"},{"key":"R77-6-20210203","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1056\/NEJM200009073431011","article-title":"The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1.","volume":"343","author":"Dinarello","year":"2000","journal-title":"N Engl J Med"},{"key":"R78-6-20210203","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1146\/annurev.immunol.021908.132612","article-title":"Immunological and inflammatory functions of the interleukin-1 family.","volume":"27","author":"Dinarello","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"R79-6-20210203","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nri2691","article-title":"The IL-1 family: regulators of immunity.","volume":"10","author":"Sims","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"R80-6-20210203","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2011.06.012","article-title":"Interleukin-1 inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).","volume":"162","author":"Ridker","year":"2011","journal-title":"Am Heart J"},{"key":"R81-6-20210203","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1161\/01.ATV.20.11.2394","article-title":"Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis.","volume":"20","author":"Dewberry","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R83-6-20210203","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1161\/01.ATV.16.8.1000","article-title":"Interleukin-1 beta in coronary arteries of patients with ischemic heart disease.","volume":"16","author":"Galea","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R84-6-20210203","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/S0735-1097(00)01014-7","article-title":"Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting.","volume":"36","author":"Kastrati","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"R85-6-20210203","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1745-6215-9-8","article-title":"Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study).","volume":"9","author":"Crossman","year":"2008","journal-title":"Trials"},{"key":"R86-6-20210203","doi-asserted-by":"crossref","first-page":"A13","DOI":"10.1136\/heartjnl-2011-300198.15","article-title":"Investigation of IL-1 Inhibition in patients presenting with non-ST elevation myocardial infarction acute coronary syndromes (the MRC ILA Heart Study).","volume":"97","author":"Morton","year":"2011","journal-title":"Heart"},{"key":"R87-6-20210203","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/eurheartj\/eht398","article-title":"Targeting inflammatory pathways for the treatment of cardiovascular disease.","volume":"35","author":"Ridker","year":"2014","journal-title":"Eur Heart J"},{"issue":"suppl 1","key":"R89-6-20210203","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1538-7836.2009.03404.x","article-title":"Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT).","volume":"7","author":"Ridker","year":"2009","journal-title":"J Thromb Haemost"},{"key":"R90-6-20210203","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.amjcard.2011.06.054","article-title":"Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease.","volume":"108","author":"Micha","year":"2011","journal-title":"Am J Cardiol"},{"key":"R91-6-20210203","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1172\/JCI2676","article-title":"Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells.","volume":"102","author":"Genestier","year":"1998","journal-title":"J Clin Invest"},{"key":"R92-6-20210203","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.4049\/jimmunol.170.10.4986","article-title":"Differential control of cell cycle, proliferation, and survival of primary T lymphocytes by purine and pyrimidine nucleotides.","volume":"170","author":"Quemeneur","year":"2003","journal-title":"J Immunol"},{"key":"R93-6-20210203","first-page":"395","article-title":"In vitro effects of methotrexate on polyamine levels in lymphocytes from rheumatoid arthritis patients.","volume":"14","author":"Nesher","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"R94-6-20210203","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/sj.bjp.0705054","article-title":"The anti-inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species.","volume":"138","author":"Phillips","year":"2003","journal-title":"Br J Pharmacol"},{"key":"R95-6-20210203","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/pr.57.2.3","article-title":"Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis.","volume":"57","author":"Cronstein","year":"2005","journal-title":"Pharmacol Rev"},{"key":"R96-6-20210203","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1016\/S0140-6736(00)02222-4","article-title":"Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity.","volume":"355","author":"Landewe","year":"2000","journal-title":"Lancet"},{"key":"R97-6-20210203","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/ard.2008.092668","article-title":"Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature.","volume":"68","author":"Visser","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R98-6-20210203","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1136\/ard.2008.093690","article-title":"Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research.","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000062","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:49:36Z","timestamp":1620949776000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045415-201509000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":91,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000062","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}